VitaNova Life Sciences (VNOV) Net Income towards Common Stockholders (2017 - 2026)
VitaNova Life Sciences (VNOV) reported Net Income towards Common Stockholders of -$44362.0 for Q1 2026, down 160.79% on a YoY basis from $72978.0 in Q1 2025, and down 223.88% quarter-over-quarter from $35810.0 in Q4 2025.
VitaNova Life Sciences (VNOV) Net Income towards Common Stockholders (2017 - 2026) Analysis & Trends
VitaNova Life Sciences has reported Net Income towards Common Stockholders for 10 years, with the latest figure at -$44362.0 in Q1 2026.
- For the quarter ending Q1 2026, Net Income towards Common Stockholders fell 160.79% year-over-year to -$44362.0; the trailing twelve-month figure through Jan 2026 stood at $745479.0 (up 241.44% YoY), and the FY2025 full-year result was $850746.0, up 503.94% from the prior year.
- Net Income towards Common Stockholders for Q1 2026 stood at -$44362.0, down from $35810.0 in the prior quarter.
- The five-year high for Net Income towards Common Stockholders was $800332.0 in Q2 2025, with the low at -$55211.0 in Q3 2024.
- Historically, Net Income towards Common Stockholders has averaged $52625.9 across 5 years, with a median of $2134.0 in 2022.
- Annual changes were most pronounced in 2023 — Net Income towards Common Stockholders slumped 1236.22% — and 2024, when it surged 3929.4%.
- VitaNova Life Sciences' Net Income towards Common Stockholders stood at $2601.0 in 2022, then plunged by 436.6% to -$8755.0 in 2023, then soared by 472.9% to $32647.0 in 2024, then grew by 9.69% to $35810.0 in 2025, then tumbled by 223.88% to -$44362.0 in 2026.
- The last three Net Income towards Common Stockholders figures came in at -$44362.0 (Q1 2026), $35810.0 (Q4 2025), and -$46301.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Akso Health | 2,315,158.81 Bn | 2,315,158.63 Bn | - | - |
| 2 | Mckesson | 92.76 Bn | 89.18 Bn | 4.04 Bn | 1.86 Bn |
| 3 | Cencora | 52.82 Bn | 50.83 Bn | 3.59 Bn | 1.63 Bn |
| 4 | Cardinal Health | 52.17 Bn | 48.39 Bn | 2.50 Bn | 380.00 Mn |
| 5 | Henry Schein | 9.19 Bn | 9.71 Bn | 1.07 Bn | -541.00 Mn |
| 6 | Accendra Health | 246.88 Mn | -90.00 Mn | 312.39 Mn | - |
| 7 | Edap Tms | 161.92 Mn | 146.92 Mn | 8.15 Mn | -9.08 Mn |
| 8 | 111 | 107.47 Mn | 25.61 Mn | 23.58 Mn | -2.32 Mn |
| 9 | Cosmos Health | 9.42 Mn | 7.26 Mn | 1.38 Mn | -2.81 Mn |
| 10 | VitaNova Life Sciences | - | - | 316,343.00 | -44,362.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jan 31, 2026 | -44,362.00 |
| Oct 31, 2025 | 35,810.00 |
| Jul 31, 2025 | -46,301.00 |
| Apr 30, 2025 | 800,332.00 |
| Jan 31, 2025 | 72,978.00 |
| Oct 31, 2024 | 32,647.00 |
| Jul 31, 2024 | -55,211.00 |
| Apr 30, 2024 | 167,919.00 |
| Jan 31, 2024 | 5,948.00 |
| Oct 31, 2023 | -8,755.00 |
| Jul 31, 2023 | -24,247.00 |
| Apr 30, 2023 | -4,385.00 |
| Jan 31, 2023 | -24,577.00 |
| Oct 31, 2022 | 2,601.00 |
| Jul 31, 2022 | 2,134.00 |
| Apr 30, 2022 | -26,807.00 |
| Jan 31, 2022 | 8,917.00 |
| Oct 31, 2021 | 15,009.00 |
| Jul 31, 2021 | 142,563.00 |
| Apr 30, 2021 | -25,563.00 |